Chioma O Erondu1, Anthony J Alberg2, Elisa V Bandera3, Jill Barnholtz-Sloan4, Melissa Bondy5, Michele L Cote6, Ellen Funkhouser7, Edward Peters8, Ann G Schwartz6, Paul D Terry9, Kristin Wallace2, Lucy Akushevich10, Frances Wang10, Sydnee Crankshaw10, Andrew Berchuck11, Joellen M Schildkraut10,12, Patricia G Moorman10. 1. 1 Duke University School of Medicine , Durham, North Carolina. 2. 2 Department of Public Health Sciences, Hollings Cancer Center, Medical University of South Carolina , Charleston, South Carolina. 3. 3 Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey , New Brunswick, New Jersey. 4. 4 Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine , Cleveland, Ohio. 5. 5 Cancer Prevention and Population Sciences Program, Baylor College of Medicine , Houston, Texas. 6. 6 Population Studies and Disparities Research Program, Department of Oncology, Wayne State University School of Medicine , Karmanos Cancer Institute, Detroit, Michigan. 7. 7 Division of Preventive Medicine, University of Alabama at Birmingham , Birmingham, Alabama. 8. 8 Epidemiology Program, Louisiana State University School of Public Health , New Orleans, Louisiana. 9. 9 Departments of Public Health and Surgery, University of Tennessee-Knoxville , Knoxville, Tennessee. 10. 10 Department of Community and Family Medicine, Duke Cancer Institute, Duke University Medical Center , Durham, North Carolina. 11. 11 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center , Durham, North Carolina. 12. 12 Department of Public Health Sciences, University of Virginia , Charlottesville, Virginia.
Abstract
BACKGROUND: Ovarian cancer, the most lethal gynecologic malignancy, typically comes to clinical attention due to nonspecific gastrointestinal or pelvic symptoms. African Americans with ovarian cancer have a greater mortality burden than whites and are also much more likely to be obese. The objective of this study is to explore whether the presentation and duration of symptoms differ by body mass index (BMI) in African Americans with ovarian cancer. METHODS: We conducted a case-only analysis using data from a multicenter population-based study of invasive epithelial ovarian cancer in African American women. Information on risk factors and symptoms leading to diagnosis was obtained in a telephone interview. Frequency and duration of symptoms by BMI categories were compared using logistic regression and linear regression analyses. RESULTS: Of the 326 women, ∼60% was obese (BMI ≥30), with 30.8% having a BMI ≥35 kg/m(2). Ninety-four percent of women reported ≥1 symptom during the year before diagnosis. We observed differences in frequency of symptoms by BMI categories, with most being reported more frequently by the heaviest women. The reported duration of symptoms was longer in women with higher BMI, with statistically significant trend tests for 6 of the 10 symptoms evaluated. CONCLUSION: BMI appears to impact ovarian cancer symptomatology. Women with higher BMI report having symptoms for a longer period of time before diagnosis of ovarian cancer. Healthcare providers should be vigilant and consider ovarian cancer in the differential diagnosis for obese women presenting with abdominal and pelvic symptoms.
BACKGROUND:Ovarian cancer, the most lethal gynecologic malignancy, typically comes to clinical attention due to nonspecific gastrointestinal or pelvic symptoms. African Americans with ovarian cancer have a greater mortality burden than whites and are also much more likely to be obese. The objective of this study is to explore whether the presentation and duration of symptoms differ by body mass index (BMI) in African Americans with ovarian cancer. METHODS: We conducted a case-only analysis using data from a multicenter population-based study of invasive epithelial ovarian cancer in African American women. Information on risk factors and symptoms leading to diagnosis was obtained in a telephone interview. Frequency and duration of symptoms by BMI categories were compared using logistic regression and linear regression analyses. RESULTS: Of the 326 women, ∼60% was obese (BMI ≥30), with 30.8% having a BMI ≥35 kg/m(2). Ninety-four percent of women reported ≥1 symptom during the year before diagnosis. We observed differences in frequency of symptoms by BMI categories, with most being reported more frequently by the heaviest women. The reported duration of symptoms was longer in women with higher BMI, with statistically significant trend tests for 6 of the 10 symptoms evaluated. CONCLUSION: BMI appears to impact ovarian cancer symptomatology. Women with higher BMI report having symptoms for a longer period of time before diagnosis of ovarian cancer. Healthcare providers should be vigilant and consider ovarian cancer in the differential diagnosis for obesewomen presenting with abdominal and pelvic symptoms.
Authors: Catherine M Olsen; Adèle C Green; David C Whiteman; Shahram Sadeghi; Fariba Kolahdooz; Penelope M Webb Journal: Eur J Cancer Date: 2007-01-12 Impact factor: 9.162
Authors: Barbara A Goff; Lynn S Mandel; Charles W Drescher; Nicole Urban; Shirley Gough; Kristi M Schurman; Joshua Patras; Barry S Mahony; M Robyn Andersen Journal: Cancer Date: 2007-01-15 Impact factor: 6.860
Authors: Patricia G Moorman; Rachel T Palmieri; Lucy Akushevich; Andrew Berchuck; Joellen M Schildkraut Journal: Am J Epidemiol Date: 2009-07-15 Impact factor: 4.897
Authors: Patricia G Moorman; Nadine J Barrett; Frances Wang; J Anthony Alberg; Elisa V Bandera; J B Barnholtz-Sloan; Melissa Bondy; Michele L Cote; Ellen Funkhouser; Linda E Kelemen; Lauren C Peres; Edwards S Peters; A G Schwartz; Paul D Terry; Sydnee Crankshaw; Sarah E Abbott; Joellen M Schildkraut Journal: J Womens Health (Larchmt) Date: 2018-11-27 Impact factor: 2.681
Authors: Delores J Grant; Ani Manichaikul; Anthony J Alberg; Elisa V Bandera; Jill Barnholtz-Sloan; Melissa Bondy; Michele L Cote; Ellen Funkhouser; Patricia G Moorman; Lauren C Peres; Edward S Peters; Ann G Schwartz; Paul D Terry; Xin-Qun Wang; Temitope O Keku; Cathrine Hoyo; Andrew Berchuck; Dale P Sandler; Jack A Taylor; Katie M O'Brien; Digna R Velez Edwards; Todd L Edwards; Alicia Beeghly-Fadiel; Nicolas Wentzensen; Celeste Leigh Pearce; Anna H Wu; Alice S Whittemore; Valerie McGuire; Weiva Sieh; Joseph H Rothstein; Francesmary Modugno; Roberta Ness; Kirsten Moysich; Mary Anne Rossing; Jennifer A Doherty; Thomas A Sellers; Jennifer B Permuth-Way; Alvaro N Monteiro; Douglas A Levine; Veronica Wendy Setiawan; Christopher A Haiman; Loic LeMarchand; Lynne R Wilkens; Beth Y Karlan; Usha Menon; Susan Ramus; Simon Gayther; Aleksandra Gentry-Maharaj; Kathryn L Terry; Daniel W Cramer; Ellen L Goode; Melissa C Larson; Scott H Kaufmann; Rikki Cannioto; Kunle Odunsi; John L Etter; Ruea-Yea Huang; Marcus Q Bernardini; Alicia A Tone; Taymaa May; Marc T Goodman; Pamela J Thompson; Michael E Carney; Shelley S Tworoger; Elizabeth M Poole; Diether Lambrechts; Ignace Vergote; Adriaan Vanderstichele; Els Van Nieuwenhuysen; Hoda Anton-Culver; Argyrios Ziogas; James D Brenton; Line Bjorge; Helga B Salvensen; Lambertus A Kiemeney; Leon F A G Massuger; Tanja Pejovic; Amanda Bruegl; Melissa Moffitt; Linda Cook; Nhu D Le; Angela Brooks-Wilson; Linda E Kelemen; Paul D P Pharoah; Honglin Song; Ian Campbell; Diana Eccles; Anna DeFazio; Catherine J Kennedy; Joellen M Schildkraut Journal: Cancer Med Date: 2019-04-18 Impact factor: 4.711